Edwards Courtney M, Johnson Rachelle W
Program in Cancer Biology, Vanderbilt University, Nashville, TN, United States.
Vanderbilt Center for Bone Biology, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Front Oncol. 2021 Mar 22;11:644303. doi: 10.3389/fonc.2021.644303. eCollection 2021.
Parathyroid hormone related protein (PTHrP) is a multifaceted protein with several biologically active domains that regulate its many roles in normal physiology and human disease. PTHrP causes humoral hypercalcemia of malignancy (HHM) through its endocrine actions and tumor-induced bone destruction through its paracrine actions. PTHrP has more recently been investigated as a regulator of tumor dormancy owing to its roles in regulating tumor cell proliferation, apoptosis, and survival through autocrine/paracrine and intracrine signaling. Tumor expression of PTHrP in late stages of cancer progression has been shown to promote distant metastasis formation, especially in bone by promoting tumor-induced osteolysis and exit from dormancy. In contrast, PTHrP may protect against further tumor progression and improve patient survival in early disease stages. This review highlights current knowledge from preclinical and clinical studies examining the role of PTHrP in promoting tumor progression as well as skeletal and soft tissue metastasis, especially with regards to the protein as a regulator of tumor dormancy. The discussion will also provide perspectives on PTHrP as a prognostic factor and therapeutic target to inhibit tumor progression, prevent tumor recurrence, and improve patient survival.
甲状旁腺激素相关蛋白(PTHrP)是一种具有多个生物活性结构域的多功能蛋白,这些结构域在正常生理和人类疾病中调节其多种作用。PTHrP通过其内分泌作用导致恶性肿瘤体液性高钙血症(HHM),并通过其旁分泌作用导致肿瘤诱导的骨破坏。由于PTHrP通过自分泌/旁分泌和胞内分泌信号传导在调节肿瘤细胞增殖、凋亡和存活方面的作用,最近它被作为肿瘤休眠的调节因子进行研究。已表明,在癌症进展后期,肿瘤表达PTHrP可促进远处转移形成,尤其是通过促进肿瘤诱导的骨溶解和从休眠状态中脱离而在骨中发生转移。相比之下,在疾病早期阶段,PTHrP可能防止肿瘤进一步进展并提高患者生存率。本综述重点介绍了临床前和临床研究的现有知识,这些研究探讨了PTHrP在促进肿瘤进展以及骨骼和软组织转移中的作用,特别是将该蛋白作为肿瘤休眠调节因子的作用。讨论还将提供关于PTHrP作为预后因素和治疗靶点以抑制肿瘤进展、预防肿瘤复发和提高患者生存率的观点。